Dual GIP/GLP-1 receptor agonist for superior blood sugar management and groundbreaking weight loss research.
Dual receptor action for enhanced weight loss results
Superior glycemic control vs single-agonist therapies
Once-weekly dosing for patient convenience
Proven cardiovascular benefits
Tirzepatide is a groundbreaking dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist that represents the next evolution in diabetes and weight loss research. Unlike single-agonist therapies, tirzepatide's dual mechanism provides superior efficacy in metabolic control.
As a novel once-weekly injection, tirzepatide has demonstrated remarkable clinical results, with research showing average weight reductions of 20-22% of body weight—significantly outperforming single-agonist therapies. Its unique dual-receptor targeting creates synergistic effects on glucose metabolism and appetite regulation.
Our research-grade tirzepatide is supplied as a lyophilized powder with complete Certificates of Analysis, ensuring the highest standards of purity and potency for your laboratory studies.
Delays stomach emptying to increase feelings of fullness and reduce appetite signals.
Targets both GIP and GLP-1 receptors for enhanced metabolic benefits.
Stimulates glucose-dependent insulin release from pancreatic beta cells.
Reduces cardiovascular risk factors including blood pressure and lipid levels.
This product is intended for laboratory research purposes only. Not for human consumption or clinical use. All purchases require consultation with a qualified healthcare provider. Tirzepatide has not been evaluated by the FDA for weight management. Please review our Certificates of Analysis for purity and quality information.
Have questions about Tirzepatide or need personalized guidance? We're here to help with any inquiries about this product.
Email Us About This ProductWe typically respond within 24 hours